MXCT vs TFC · rev $38.6M vs rev $24.54B
MaxCyte Inc (MXCT) versus TFC (TFC) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
TFC (TFC) common stock.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TFC revenue for 2025-12-31 was $24.54B. Net income was $5.31B. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. TFC currently screens at market cap $0.
MXCT currently screens at market cap $124.3M. TFC currently screens at market cap $0.
Not investment advice. Open the MXCT and TFC stock pages for the full models.
Not investment advice.